NCT03879382Unknown1 期
A Phase I Clinical Trial of Human CD19/BCMA Bispecific CAR-T Cell Therapy for Subjects With Relapsed and Refractory POMES Syndrome.
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 入组人数
- 10
- 试验地点
- 1
- 主要终点
- Safety measured by occurrence of study related adverse effects defined by NCI CTCAE 4.0
研究概览
简要总结
The goal of this clinical trial is to study the feasibility and efficacy of anti-CD19/BCMA bispecific chimeric antigen receptors (CARs) T cell therapy for relapsed and refractory POMES Syndrome.
详细描述
Primary Objectives
- To determine the feasibility ad safety of anti-CD19/BCMA CAR-T cells in treating patients with relapsed and refractory POMES Syndrome.
Secondary Objectives
- To access the efficacy of anti-CD19/BCMA CAR-T cells in patients with POMES Syndrome.
- To determine in vivo dynamics and persistency of anti-CD19/BCMA CAR-T cells.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Expected survival > 12 weeks;
- •Diagnosis of POMES Syndrome;
- •The criteria for relapsed and refractory POMES Syndrome: patients previously received at least 3 different prior treatment regimens for multiple myeloma, including Alkylating agent and other protein inhibitors (eg: Bortezomib), and have disease progression in the past 60 days;
- •At least 90 days after stem cell transplantation;
- •Creatinine≤2.0 mg/dl;
- •Bilirubin≤2.0 mg/dl;
- •The ALT/AST value is lower than 2.5-fold of normal value;
- •Accessible to intravenous injection, and no white blood cell collection contraindications;
- •Sexually active patients must be willing to utilize one of the more effective birth control methods for 30 days after the CTL infusion. Male partner should use a condom;
- •5mg/day dose of Prednisone or other equivalent steroid hormone drugs (eg: Dexamethasone) were not used for two weeks before apheresis and CAR-T infusion;
- •Able to understand and sign the Informed Consent Document.
排除标准
- •• In the first 5 years before screening, there are malignant tumors other than POMES Syndrome, except for fully treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, local prostate cancer after radical surgery，and catheter carcinoma in situ after radical surgery;
- •Hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) positive and peripheral blood HBV DNA titer higher than the upper limit of detection; hepatitis C virus (HCV) antibody positive and peripheral blood HCV RNA positive; human immunodeficiency Viral (HIV) antibody positive; Positive syphilis test;
- •Any unstable systemic disease including, but not limited to, active infection (except for local infection), unstable angina pectoris, cerebrovascular accident or transient cerebral ischemia (within 6 months prior to screening), myocardial infarction (within 6 months prior to screening), congestive heart failure (New York Heart Association [NYHA] classification ≥ III), severe arrhythmia, liver, kidney or metabolic disease requiring medication;
- •Any other diseases could affect the outcome of this trial;
- •Any affairs could affect the safety of the subjects or outcome of this trial;
- •Pregnant or lactating women, or planned pregnancy during treatment or within 1 year after treatment, or a male subject whose partner plans pregnancy within 1 year of their cell transfusion;
- •Active or uncontrollable infection requiring systemic therapy within 14 days prior to enrollment;
- •Subjects who are receiving systemic steroid treatment and requiring long-term systemic steroid treatment during the treatment as determined by the investigator before screening (except inhalation or topical use); And subjects treated with systemic steroids (except inhalation or topical use) within 72h prior to cell transfusion;
- •Received CAR-T treatment or other gene therapies before enrollment;
- •Patients with symptoms of central nervous system or brain metastasis or have received treatment for central nervous system or brain metastasis (radiotherapy, surgery or other treatment) within 3 months before enrollment;
- •Subject suffering disease affects the understanding of informed consent or comply with study protocol;
- •The investigators consider other conditions unsuitable for enrollment.
研究组 & 干预措施
anti-CD19/BCMA CAR-T cells
Experimental
Administration with anti-CD19/BCMA CAR-T cells in the relapsed and refractory POMES Syndrome patients
干预措施: Cyclophosphamide (Drug)
anti-CD19/BCMA CAR-T cells
Experimental
Administration with anti-CD19/BCMA CAR-T cells in the relapsed and refractory POMES Syndrome patients
干预措施: anti-CD19/BCMA CAR-T cells (Biological)
anti-CD19/BCMA CAR-T cells
Experimental
Administration with anti-CD19/BCMA CAR-T cells in the relapsed and refractory POMES Syndrome patients
干预措施: Fludarabine (Drug)
结局指标
主要结局
Safety measured by occurrence of study related adverse effects defined by NCI CTCAE 4.0
时间窗: 6 months
Safety measured by occurrence of study related adverse effects defined by NCI CTCAE 4.0
次要结局
- Duration of CAR-positive T cells in circulation(6 months)
- Overall complete remission rate defined by the standard response criteria for POMES Syndrome(8 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
1 期
Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R MMMultiple Myeloma in RelapseMultiple Myeloma ProgressionNCT03706547Peng Liu20
Unknown
1 期
Anti-CD19/CD22 Bispecific CAR-T Cell Therapy for CD19-positive ALLCD19-positive ALLNCT04303520The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine20
暂停
1 期
Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic LeukemiaRecurrent Acute Lymphoblastic LeukemiaRefractory Acute Lymphoblastic LeukemiaNCT06447987City of Hope Medical Center24
Unknown
1 期
CD19 CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma and B-cell Acute Lymphoblastic LeukemiaB Cell LymphomaB-cell Acute Lymphoblastic LeukemiaNCT03854994Yan'an Affiliated Hospital of Kunming Medical University10
招募中
1 期
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell MalignanciesNon Hodgkin Lymphoma (NHL)Mantle Cell Lymphoma (MCL)Chronic Lymphocytic Leukemia (CLL)Marginal Zone LymphomaDiffuse Large B Cell LymphomaPrimary Mediastinal Large B-cell Lymphoma (PMBCL)Central Nervous System LymphomaFollicular LymphomaNCT04186520Medical College of Wisconsin100